London - HIKMA PHARMACEUTICALS PLC ('Hikma') announces today that it has purchased the following number of its ordinary shares on the London Stock Exchange, Aquis Stock Exchange Limited and CBOE Europe Limited through the BXE and CXE order books from Morgan Stanley & Co. International plc.

The repurchased shares will be cancelled.

Such purchases form part of Hikma's share buyback programme announced on 24 February 2022, 11 April 2022 and 11 May 2022.

Following the settlement of the above purchases and cancellation of the purchased ordinary shares, the total number of ordinary shares in issue shall be 234,687,806 ordinary shares and the total number of ordinary shares held in treasury is 12,833,233 ordinary shares. Therefore, following the above purchases total voting rights are 221,854,573 ordinary shares.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), the detailed breakdown of individual trades made by Morgan Stanley on behalf of Hikma as part of the buyback programme is set out below.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

Contact:

Peter Speirs

Tel: +44 (0)20 7399 2772

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

(C) 2022 Electronic News Publishing, source ENP Newswire